CureVac NV
NASDAQ:CVAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.4), the stock would be worth $9.56 (105% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | $4.66 |
0%
|
| 3-Year Average | 1.4 | $9.56 |
+105%
|
| 5-Year Average | 2.5 | $16.67 |
+258%
|
| Industry Average | 1.7 | $11.25 |
+141%
|
| Country Average | 1 | $6.37 |
+37%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
CureVac NV
NASDAQ:CVAC
|
1B USD | 0.7 | 6.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 4.6 | 89.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 3.8 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 3.7 | 19.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 7.5 | 27.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 5.6 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 1.5 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 1 |
| 70th Percentile | 1.6 |
| Max | 298.9 |
Other Multiples
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
